RXRX Recursion Pharmaceuticals, Inc.
Recursion Pharmaceuticals, Inc. (RXRX) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 100% planned / 0% discretionary
Largest single sale: $158.5K.
Where they traded
No open-market insider purchase on record.
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Khan Najat | CEO and President | Sell 10b5-1 | 22,408 | $3.52 | $78.8K | 2,072,890 −1.1% of holding | |
| Borgeson Blake | Director | Sell 10b5-1 | 30,000 | $3.34 | $100.2K | 6,158,287 −0.5% of holding | |
| Borgeson Blake | Director | Sell 10b5-1 | 30,000 | $3.25 | $97.5K | 6,188,287 −0.5% of holding | |
| Borgeson Blake | Director | Sell 10b5-1 | 40,000 | $3.96 | $158.5K | 6,218,287 −0.6% of holding | |
| Bumpus Namandje | Director | Sell 10b5-1 | 3,963 | $3.18 | $12.6K | 127,632 −3% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.